Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM15211 in Subjects With Biopsy Confirmed NASH
NCT04505436Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Jun 2026
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing HM15211 with Placebo (2 arms). Primary endpoint: Pharmacodynamic effect at 12 months. Started Jul 2020; status: completed.
02
Drugs
efocipegtrutide
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04505436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505436.